TLSANCMHealthcare·Biotechnology#335 in industry

Tiziana Life Sciences Ltd

-25.9% · 90d

$1.26

-0.03 (-2.33%)

After-Hours $1.26(+0.00)

News

(1)

April 2026

Apr 1, 20263 weeks ago6-KHealthcare

Tiziana Life Sciences Ltd — 6-K Filing

TLSATiziana Life Sciences Ltd

# 🔬 What This Document Is This is a 6-K filing from Tiziana Life Sciences, which is essentially a report the company files with the SEC to share important news with investors. The attached press release announces new preclinical (lab study) data for their drug candidate, intranasal foralumab. 👉

Read summaryView on SEC EDGAR

Key Data

Market Cap$160.3M

Open$1.29

Prev Close$1.29

Day Range$1.23 – $1.33

52W Range$1.14 – $2.60

Volume87,037

P/E (TTM)—

EPS$-0.12

Dividend Yield—

Beta0.37

Price Target$8.03(+537.2%)

About

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Healthcare · Biotechnology

9 employees

www.tizianalifesciences.com